TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases. It has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited. in Mainland China, Hong Kong, and Macao markets. TWi Biotechnology, Inc. was founded in 2010 and is based in Taipei, Taiwan.
Frequently asked questions
What sector does TWi Biotechnology, Inc. (6610) operate in?
TWi Biotechnology, Inc. belongs to the Other sector and operates in the Biotechnology industry.
What is TWi Biotechnology, Inc. (6610) current stock price?
As of the latest data, TWi Biotechnology, Inc. stock price is NT$27.10, with a previous close of NT$26.80. TWi Biotechnology, Inc. gained NT$0.30 in the last trading session, representing a 1.12% increase.
What is TWi Biotechnology, Inc. (6610) current market capitalization?
TWi Biotechnology, Inc. market cap is approximately 5.63 billion.
What is TWi Biotechnology, Inc. (6610) Earnings Per Share (EPS)?
The trailing EPS is -NT$1.82.
Does TWi Biotechnology, Inc. (6610) pay dividends?
No. TWi Biotechnology, Inc. does not pay a dividend.
What is TWi Biotechnology, Inc. (6610) beta (volatility) score?
TWi Biotechnology, Inc. has a beta of 0.978, meaning its volatility is roughly in line with the market.
